A Study of Inhaled Ampion in Adults With Respiratory Distress Due to COVID-19

Summary

This is phase II study to evaluate the safety and efficacy of inhaled Ampion in adults with respiratory distress due to COVID-19

Timeline

Start

2021-06-22

Primary completion

2022-02-16

Completion

2022-04-13

Outcome

Outcome not reported

Stopped: “The AP-019 study was prematurely terminated by the sponsor after determining that insufficient events were occurring to analyze the primary endpoint.”

Drugs

Indications